The evolution of cancer therapeutics: from “undruggable” to “drugged”
Translational Cancer Research · 2026-07 · 15 (7) · 514-514
DOI: 10.21037/tcr-2026-0807 ↗Kurz gefasst
Editorial in der Zeitschrift Translational Cancer Research, 2026-07. Verfasst von Daniel Neureiter und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, Paracelsus Medical University/University Hospital Salzburg (SALK), Salzburg, Austria. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Pathology, Paracelsus Medical University/University Hospital Salzburg (SALK), Salzburg, Austria.
- Cancer Cluster Salzburg, Salzburg, Austria.
- Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Campus Charité Mitte, Charité University Medicine Berlin, Berlin, Germany.
- EO Translational Insights Consulting GmbH, Berlin, Germany.
- Tacalyx GmbH, Berlin, Germany.
ORCID-Profile: Daniel Neureiter, Matthias Ocker
Zitieren
APA
Neureiter, D., & Ocker, M. (2026). The evolution of cancer therapeutics: from “undruggable” to “drugged”. Translational Cancer Research, 15(7), 514-514. https://doi.org/10.21037/tcr-2026-0807
Vancouver
Neureiter D, Ocker M. The evolution of cancer therapeutics: from “undruggable” to “drugged”. Translational Cancer Research. 2026;15(7):514-514. doi:10.21037/tcr-2026-0807
BibTeX
@article{Neureiter2026,
author = {Neureiter, Daniel and Ocker, Matthias},
title = {The evolution of cancer therapeutics: from “undruggable” to “drugged”},
journal = {Translational Cancer Research},
year = {2026},
volume = {15},
number = {7},
pages = {514--514},
doi = {10.21037/tcr-2026-0807}
}
EUVIMED